Metabolic syndrome
Conditions
Interventions
Ezetimibe 10mg daily,during the study period.
control
Sponsors
Tohoku University Graduate School of Medicine EZET-trial group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria. 1) Patients with Metabolic syndrome who are 20 years or older and less than 80 years at the entry. 2) Serum LDL cholesterol is 120mg/dl or over and less than 180mg/dl. 3) Patients who do not receive any lipid-lowering agents.
Exclusion criteria
Exclusion criteria: 1) History of drug hypersensitivity to ezetimibe. 2) History of chronic heart failure. 3) Patients who have insulin therapy. 4) Patients who have severe liver dysfunction. Patients who have severe kidney dysfunction. 5) Patients who have secondary dyslipidemia or drug-induced dyslipidemia. 6) Pregnant or possibly pregnant patients. 7) Other patients deemed unsuitable as subjects of the study by the treating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rho-kinase activity FMD(flow-mediated dilation) | — |
Secondary
| Measure | Time frame |
|---|---|
| serum total and LDL cholesterol serum triglyceride cholesterol absorption marker adiponectin high sensitive CRP | — |
Countries
Japan
Contacts
Public ContactKotaro Nochioka
Tohoku University Graduate School of Medicine Department of Cardiovascular Medicine
Outcome results
None listed